Don’t Consider Sotagliflozin a Diabetes Med
July 2023
New Rx sotagliflozin (Inpefa) will join dapagliflozin (Farxiga), empagliflozin (Jardiance), and other SGLT2 inhibitors.
But sotagliflozin is the only SGLT2 inhibitor NOT yet approved for treating type 2 diabetes.
It’s currently only approved to reduce the risk of heart failure urgent care visits and hospitalizations and cardiovascular death...in certain adults with OR without diabetes.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote